source
- Investors Re-evaluate Kidney Disease as New Cell and Gene Therapy Strategies EmergeIn a recent episode of BioSpace's Denatured podcast, the CEOs of ProKidney and Nephrogen discussed why kidney disease has long been a difficult indication for cell and gene-based medicines. The co…
- Roche touts strong Phase 3 track record while trimming pipeline amid peer setbacksRoche's chief executive Thomas Schinecker highlighted the company's high success rate in Phase 3 trials, positioning it as a competitive advantage. The comment accompanied an announcement that Roc…